Hydroquinone: myths and reality.
Administration, Cutaneous
Adrenal Cortex Hormones
/ administration & dosage
Drug Therapy, Combination
Humans
Hydroquinones
/ administration & dosage
Hyperpigmentation
/ drug therapy
Monophenol Monooxygenase
/ antagonists & inhibitors
Ochronosis
/ chemically induced
Ointments
Retinoids
/ administration & dosage
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
21
09
2020
received:
08
08
2020
accepted:
26
09
2020
pubmed:
8
11
2020
medline:
16
11
2021
entrez:
7
11
2020
Statut:
ppublish
Résumé
Hydroquinone has pharmacological uses in disorders of pigmentation because of its ability to competitively inhibit the enzyme tyrosinase. Our contemporary review presents the strongest evidence supporting the use of hydroquinone with the most effective and tolerable formulations combining hydroquinone, retinoid and corticosteroid (modified Kligman formula or 'triple combination cream'). The risk of exogenous ochronosis is low if prescribed concentrations of ≤ 5 for a limited period with regular monitoring. Dermatologists should reassure patients that with controlled use, hydroquinone can be well-tolerated and safe for a range of hyperpigmentary conditions.
Substances chimiques
Adrenal Cortex Hormones
0
Hydroquinones
0
Ointments
0
Retinoids
0
Monophenol Monooxygenase
EC 1.14.18.1
hydroquinone
XV74C1N1AE
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
636-640Informations de copyright
© 2020 British Association of Dermatologists.
Références
Schwartz C, Jan A, Zito PM. Hydroquinone. Updated 2020. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. Available at: https://www.ncbi.nlm.nih.gov/books/NBK539693/ (accessed 16 July 2020).
Sarkar R, Arora P, Garg KV. Cosmeceuticals for hyperpigmentation: what is available? J Cutan Aesthet Surg 2013; 6: 4-11.
Chang MW. Disorders of hyperpigmentation. Chapter 10. In: Dermatology, 2nd edn (Bolognia JL, Jorizzo JL, Rapini RP, ed). New York: Mosby, 2003; 1049-74.
Jimbow K, Obata H, Pathak MA, Fitzpatrick TB. Mechanism of depigmentation by hydroquinone. J Invest Dermatol 1974; 62: 436-49.
Prignano F, Ortonne JP, Buggiani G, Lotti T. Therapeutic approaches to melasma. Dermatol Clin 2007; 25: 337-42.
Ennes SB, Paschoalick RC, Alchorne MM. A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. J Dermatol Treat 2000; 11: 173-9.
Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975; 111: 40-8.
Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol 2009; 54: 303-9.
Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol 2006; 54: S272-81.
Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther 2007; 20: 308-13.
Kandhari R, Khunger N. Skin lightening agents - use or abuse? A retrospective analysis of the topical preparations used by melasma patients of darker skin types. Indian J Dermatol Venereol Leprol 2013; 79: 701-2.
Chandra M, Levitt J, Pensabene CA. Hydroquinone therapy for post-inflammatory hyperpigmentation secondary to acne: not just prescribable by dermatologists. Acta Derm Venereol 2012; 92: 232-5.
Grimes PE, Bhawan J, Guevara IL et al. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. J Am Acad Dermatol 2010; 62: 962-7.
Arellano I, Cestari T, Ocampo-Candiani J et al. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity. J Eur Acad Dermatol Venereol 2012; 26: 611-18.
Bhawan J, Grimes P, Pandya AG et al. A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. Am J Dermatopathol 2009; 31: 794-8.
Bhattar PA, Zawar VP, Godse KV et al. Exogenous ochronosis. Indian J Dermatol 2015; 60: 537-43.
Penneys NS. Ochronosis like pigmentation from hydroquinone bleaching creams. Arch Dermatol 1985; 121: 1239-40.
Baca IM, Al-Niaimi F, Colina C, Anuzita A. A case of ochronosis successfully treated with the picosecond laser. J Cosmet Dermatol 2019; 18: 1322-5.
Draelos ZD. The latest cosmeceutical approaches for anti-aging. J Cosmet Dermatol 2007; 6: 2-6.
Levitt J. The safety of hydroquinone: a dermatologist's response to the 2006 Federal register. J Am Acad Dermatol 2007; 57: 854-72.
Tse TW. Hydroquinone for skin lightening: safety profile, duration of use and when should we stop? J Dermatol Treat 2010; 21: 272-5.
Levin CY, Maibach H. Exogenous ochronosis: an update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2: 213-17.
Burke P, Maibach H. Exogenous ochronosis: an overview. J Dermatol Treat 1997; 8: 21-6.
British Association of Dermatologists. Melasma. Updated March 2018. Available at: https://www.bad.org.uk/shared/get-file.ashx?id=169&itemtype=document (accessed 2 August 2018).